# MiNK Therapeutics (INKT) — News

INKT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/inkt/news

## Recent headlines

- [MIA Teknoloji - Company expects to generate about 21.6 mln lira in revenue from agreement](https://www.ainvest.com/news/mia-teknoloji-company-expects-generate-21-6-mln-lira-revenue-agreement-2610) — AInvest Wire, Oct 15, 2026
  Mia Teknoloji A.Ş. (MIATK) is anticipated to generate approximately 21.6 million Turkish lira in revenue from a recent agreement, according to available data. The company has been actively expanding its operations through strategic partnerships and project developments, including a recent…
- [Inwit rises 8.9% on Tradegate vs Milan close](https://www.ainvest.com/news/inwit-rises-8-9-tradegate-milan-close-2610) — AInvest Wire, Oct 12, 2026
- [Mink Therapeutics selected for ARPA-H-funded initiative to advance room-temperature cell therapy](https://www.ainvest.com/news/mink-therapeutics-selected-arpa-funded-initiative-advance-room-temperature-cell-therapy-2609) — AInvest Wire, Sep 30, 2026
  Mink Therapeutics has been selected to participate in an initiative funded by the Advanced Research Projects Agency for Health (ARPA-H), aimed at advancing room-temperature cell therapy . This development is part of a broader effort to reduce logistical barriers in cell therapy delivery, which…
- [Saga Furs OyJ - Sells entire offering of 3.9 mln mink pelts at auction](https://www.ainvest.com/news/saga-furs-oyj-sells-entire-offering-3-9-mln-mink-pelts-auction-2609) — AInvest Wire, Sep 23, 2026
  Saga Furs OyJ has successfully sold its entire offering of 3.9 million mink pelts at an auction, marking a significant development in the fur industry. The auction, which took place recently, attracted strong interest from buyers, resulting in the full sale of the company’s inventory. This outcome…
- [Mink Therapeutics to report second quarter 2026 financial results, provide clinical updates on Agent-797 in lung injury, and highlight important business updates](https://www.ainvest.com/news/mink-therapeutics-report-quarter-2026-financial-results-provide-clinical-updates-agent-797-lung-injury-highlight-important-business-updates-2608) — AInvest Wire, Aug 6, 2026
  MiNK Therapeutics (NASDAQ: INKT) announced on August 6, 2026, that it will report its second quarter 2026 financial results and provide clinical updates on agenT-797, its lead allogeneic invariant natural killer T (iNKT) cell therapy, in the treatment of acute lung injury . The company will also…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).